Search research articles
Contact Us
Filters
Showing results (61-70 of 101) with videos related to
Page
of 11
Sort By:
Haematologica
|
February 26, 2026
Prognostic implications of myelodysplasia-related gene mutations in <i>NPM1</i>-mutated acute myeloid leukemia: a systematic review and meta-analysis
Yu-Sung Chang, Yi-Wei Lee, Chieh-Yu Liu, et al.
Leukemia
|
May 23, 2021
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
Patrick Harrington, Hugues de Lavallade, Katie J Doores, et al.
Blood
|
August 12, 2022
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
Sun Loo, Richard Dillon, Adam Ivey, et al.
Blood
|
November 6, 2024
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Maria Teresa Voso, Luca Guarnera, Söhren Lehmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Ing Soo Tiong, Devendra K Hiwase, Emad Abro, et al.
British Journal of Haematology
|
June 4, 2021
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia
Patrick Harrington, Katie J Doores, Deepti Radia, et al.
Blood Advances
|
May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Blood Cancer Journal
|
April 23, 2022
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
Patrick Harrington, Katie J Doores, Jamie Saunders, et al.
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
CCAAT-enhancer binding protein delta functions as a tumor suppressor gene in acute myeloid leukemia
Subhash C Prajapati, Cem Meydan, Yaseswini Neelamraju, et al.
The Journal of Experimental Medicine
|
March 21, 2019
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Faisal Basheer, George Giotopoulos, Eshwar Meduri, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 101) with videos related to
Sort By:
Page
of 11
Haematologica
|
February 26, 2026
Prognostic implications of myelodysplasia-related gene mutations in <i>NPM1</i>-mutated acute myeloid leukemia: a systematic review and meta-analysis
Yu-Sung Chang, Yi-Wei Lee, Chieh-Yu Liu, et al.
Leukemia
|
May 23, 2021
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
Patrick Harrington, Hugues de Lavallade, Katie J Doores, et al.
Blood
|
August 12, 2022
Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome
Sun Loo, Richard Dillon, Adam Ivey, et al.
Blood
|
November 6, 2024
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project
Maria Teresa Voso, Luca Guarnera, Söhren Lehmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2024
Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
Ing Soo Tiong, Devendra K Hiwase, Emad Abro, et al.
British Journal of Haematology
|
June 4, 2021
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia
Patrick Harrington, Katie J Doores, Deepti Radia, et al.
Blood Advances
|
May 12, 2023
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
Jad Othman, Charlotte Wilhelm-Benartzi, Richard Dillon, et al.
Blood Cancer Journal
|
April 23, 2022
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
Patrick Harrington, Katie J Doores, Jamie Saunders, et al.
Biorxiv : the Preprint Server for Biology
|
September 5, 2025
CCAAT-enhancer binding protein delta functions as a tumor suppressor gene in acute myeloid leukemia
Subhash C Prajapati, Cem Meydan, Yaseswini Neelamraju, et al.
The Journal of Experimental Medicine
|
March 21, 2019
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML
Faisal Basheer, George Giotopoulos, Eshwar Meduri, et al.
Page
of 11